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General practice
Performance indicators for primary care groups:
an evidence based approach
Alastair McColl, Paul Roderick, John Gabbay, Helen Smith, Michael Moore
In England primary care groups will have a key role in
promoting the health and improving the health care of
their local population.1 By April 1999 these groups,
involving all primary care professionals, will provide
and commission health care for roughly 100 000
people in each locality. Primary care groups will be
accountable to health authorities and “will agree
targets for improving health, health services and value
for money.”1 There will be several primary care groups
in each district health authority. This new approach
offers primary care the opportunity to further
integrate health promotion and health care at the indi›
vidual and population levels.
The present UK government intends to manage
the performance of the “new NHS”; the word perform›
ance appeared 88 times in its recent white paper.1 It
has published a national framework for assessing per›
formance as a consultation document,2 and primary
care groups within health authorities will be judged to
have “performed” well on the basis of the indicators
listed in table 1. Most are attributable in part to
primary care, but only some are linked to interventions
that will necessarily lead to improved health outcomes.
The government has also proposed four targets for
England in its green paper Our Healthier Nation.3
Approaches taken by health authorities, and presum›
ably by primary care groups, will be “fully monitored
by the Regional Offices of the NHS Executive.”3 These
targets for reduced death rates from heart disease and
stroke, cancer, suicide, and accidents are all outcome
indicators but, again, are only partly attributable to
primary care.
Performance indicators for practices—Previous govern›
ments have attempted to use performance indicators
for group practices of general practitioners, such as
those linked to payments for uptake of immunisations
and cervical smears. Health authorities have also tried
to use practice based performance indicators,4 with
varying degrees of success.5 6 The recent availability of
data on prescribing analysis and cost has allowed
health authorities to look at practice prescribing in
more detail and to develop indicators reflecting “good
and bad” prescribing.7 Campbell et al have identified a
number of valid practice indicators from over 240
under consideration for use by health authorities in
England and Wales.8
Performance indicators for primary care groups—To
maximise their usefulness, performance indicators for
primary care groups should meet certain minimal cri›
teria before any consideration of their introduction
into routine use. They should be attributable to health
care,9 sensitive to change,10 based on reliable and valid
information, precisely defined, reflect important
clinical areas, and include a variety of dimensions of
care. The US National Library of Healthcare Indicators
describes several “definable, measurable and improv›
able domains of performance” for its indicators.11
These are attributes of organisational performance
related to “doing the right things” (such as appropri›
ateness, availability, and efficacy) and “doing things
right” (such as effectiveness, efficiency, respect and car›
ing, safety, and timeliness).11 For those indicators that
reflect appropriateness, availability, efficacy, and effec›
tiveness there should be robust evidence that the inter›
ventions on which they are based lead to improved
health outcomes. Use of such indicators to monitor
performance may be one way to promote the wider use
of evidence based interventions—for example, in the
secondary prevention of coronary heart disease.12 13
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However, there is more to primary care than the
use of evidence based interventions. Other important
dimensions to primary care include consultation skills,
the advocacy role of members of the primary care
team for individual patients, communication within the
practice team, access to primary care, managing a busi›
ness within a regulatory framework, and coordination
with community, secondary care, and local authority
services. The use of evidence based interventions and
related performance indicators as presented in this
paper can therefore only represent some aspects of
primary care. Further research is needed to address the
feasibility of developing meaningful performance
indicators reflecting these other dimensions.
The aim of our study was to develop a method to
identify important, evidence based interventions in
primary care suitable for linking to performance indi›
cators for primary care groups. Our objectives were to
(a) identify interventions of proved efficacy for
which primary care teams have a key responsibility;
(b) estimate the number of preventable deaths or
events in a primary care group locality of 100 000
people if all those eligible were receiving the interven›
tion; and (c) compare the potential indicators we
derived with the indicators currently proposed by the
government.
Methods
There is no simple definition of primary care.14 Aspects
of primary care include general practice, community
nursing, midwifery, health visiting, pharmacy, dentistry,
optometry, and other professions. For the purpose of
this study, we identified primary care interventions of
proved efficacy from systematic reviews and for which
we judged primary care teams to have the major
responsibility. We searched the Cochrane Database of
Systematic Reviews and the Database of Abstracts of
Reviews of Effectiveness15 and Effective Health Care bul›
letins and obtained the primary sources referred to in
the abstracts.
Mant and Hicks proposed a method to compare
the relative sensitivity of indicators to monitor
differences in care for the hospital treatment of
myocardial infarction.10 We developed their approach
and for each primary care intervention estimated:
Table 1 Indicators proposed in national framework for assessing performance2 that are most relevant to primary care
Performance indicators Available data source Attributable to health care
Evidence that improved indicator
value leads to improved health
outcomes
Fair access
To elective surgery: rates of CABG and PTCA, of hip and knee
replacement, and of cataract replacement
Yes Yes Unclear what ideal rates should be.
Only effective if performed on
appropriate patients
To family planning services: conception rates for those aged <16 Yes Limited extent Yes
To cancer screening services: % of target population screened
for breast and cervical cancer
Yes Yes, but people can refuse Yes, though evidence for cervical
screening based on observational data
To district nurse contacts: district nurse and assisted district
nurse contacts for those aged >75, and district nurse
contacts lasting >30 minutes for same age group
Yes Yes No
Effective delivery of appropriate health care
% of target population vaccinated and % of all orchidopexies for
those aged <5
Yes Yes, but people can refuse
vaccination
Vaccination, yes; orchidopexy, limited
extent
% of target population screened for breast and cervical cancer
(as above)
Yes Yes, but people can refuse Yes, though evidence for cervical
screening based on observational data
Rates of CABG and PTCA, of hip and knee replacement, and of
cataract replacement
Yes Yes Only effective if performed on
appropriate patients
Age and sex standardised admission rates for severe ENT
infection, kidney or urinary tract infection, heart failure
(“avoidable admissions”)
Yes Yes, but patients can self
refer to accident and
emergency units
Unclear how
Age and sex standardised admission rates for asthma, diabetes,
and epilepsy (“largely managed in a primary care setting”)
Yes Yes, but patients can self
refer to accident and
emergency units
Unclear how
Volume of prescribing of benzodiazepines, and ratio of
antidepressants to benzodiazepines
Yes Yes To some extent
Composite measure of prescribing of combination and modified
release products plus “drugs of limited clinical value” and
inhaled corticosteroids
Yes Yes To some extent
Efficiency
% generic prescribing Yes Yes No, but savings made can be invested
in effective interventions
Health outcomes of NHS care
Conception rates for those aged <16 Yes Limited extent Yes as this is a health outcome
indicator
Notification rates for pertussis and measles Yes Yes Yes as this is a health outcome
indicator
Emergency hospital admissions for people aged >75 Yes To some extent, but also
reflects social provision
Possibly, but definition of emergency
may vary
Rates of emergency psychiatric readmission Yes To some extent, but also
reflects social provision
Possibly, but definition of emergency
may vary
CABG=coronary artery bypass graft; PTCA=percutaneous transluminal coronary angioplasty; ENT=ear, nose, and throat.
The indicators in the other categories—“Health improvement” (deaths from all causes and cancer registrations) and “Patient/carer experience of the NHS”—are less
relevant to primary care.
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(a) Reduced risk of death or events for those receiving
the intervention compared with those not receiving it
over a certain period—the relative risk reduction (%)
(b) Mortality or event rate of those not receiving the
intervention (the controls) over a certain period
(c) The difference in risk of death or events between
those receiving the intervention and those not
receiving it—the absolute risk reduction (a × b)
(d) The number of patients needed to receive the inter›
vention in order to prevent one of them dying or
developing an adverse event—the number needed to
treat (1/c, the reciprocal of the absolute risk
reduction16)
(e) The proportion (and number) of patients likely to
be eligible to receive the intervention in a locality of
100 000
(f) The adjusted relative risk reduction to take into
account those eligible for the intervention over a
certain period (a × e)
(g) The adjusted absolute risk reduction (c× e%) and
number of preventable deaths or events in the locality
over a certain period if all those eligible received the
intervention
(h) Current rate of uptake of the intervention in those
eligible in the primary care group (estimated from
published studies, local data, or local opinion)
(i) Additional number of preventable deaths or events
if all those eligible in the locality received the interven›
tion (g× (1 − h)).
We also made brief comments on the interventions
such as potential side effects and whether the interven›
tion was likely to be cost effective.
Estimates of the potential impact of
interventions
Table 2 lists the primary care interventions we
examined and whether we were able to obtain key
information as described in the previous section. For
the purposes of this brief discussion, we focus our illus›
trative method on the first eight interventions listed for
which we were able to easily translate risk reduction
into improvement in health outcome.
Table 3 shows the relative risk reductions for these
eight interventions together with the number of
patients likely to be eligible in a locality and the
Table 2 Availability of evidence or information on primary care interventions
Intervention
Availability of information
Comments
Relative
risk
reduction
Absolute
risk
reduction
% of
patients
eligible
Current uptake
rate in those
eligible
Cost
effectiveness
Risk reduction translated to
improved health outcome
at population level
Aspirin for patients at high risk of
coronary or ischaemic
cerebrovascular events
fYes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Control of hypertension Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Advice on stopping smoking or
nicotine replacement therapy
Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Angiotensin converting enzyme
inhibitors for patients with
heart failure
Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Statins for patients at high risk of
coronary heart disease
(secondary prevention)
Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Statins for patients at low risk of
coronary heart disease
(primary prevention)
Yes Yes Yes No Yes Yes Further details in tables 3 and 4
Warfarin for stroke prophylaxis in
non›valvular atrial fibrillation
Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Influenza vaccination for those
aged >65
Yes Yes Yes Yes Yes Yes Further details in tables 3 and 4
Diabetes care Yes Yes Yes Yes Yes No Diabetes care in general practice can achieve
standards of care equivalent to or better than hospital
outpatient care but does not lead to reduced mortality
or hospital admissions.17 Difficult to translate other
reported end points such as glycaemic control and
losses to follow up into outcomes such as non›fatal
events
Cervical screening No No Yes Yes Yes No Observational data suggest that cervical screening
programmes are effective. Difficult to translate such
observational data into relative and absolute risk
reductions
Brief interventions to reduce
alcohol consumption
Yes Yes Yes Yes Yes No Unable to translate evidence on efficacy in reducing
alcohol consumption18 into improved health outcomes
(fatal and non›fatal events) at population level
Contraceptive prescribing with
family planning advice
No No Yes Yes Yes No Experimental and observational evidence of relative
effectiveness of different contraceptives. Difficult to
translate such data into relative and absolute risk
reductions between users and non›users
Immunisations (except against
influenza in elderly)
No No Yes Yes Yes No Observational data strongly suggest that immunisation
programmes are effective.19 Difficult to translate such
observational data into relative and absolute risk
reductions
Treatment of obesity in adults Yes Yes Yes Yes Yes No Unable to translate evidence of efficacy in reducing
weight20 into improved health outcomes (fatal and
non›fatal events) at population level
Yes=evidence or information readily available. No=evidence or information not readily available.
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number of preventable deaths or events in the locality
if all those eligible received the intervention. (Full
details of how we estimated stages (a) to (i) for
each intervention and the assumptions we made
are listed in the appendices on the BMJ website).
Some interventions, despite having high numbers
needed to treat, could have a considerable impact on
the health of a population. For example, 108 people
aged over 65 need to receive influenza vaccination
each year to prevent one death, but in a population of
100 000 this intervention could prevent 146 deaths
each year.
Table 4 shows the estimated current uptake for
each intervention, the additional number of prevent›
able events if all eligible patients receive the
intervention, and, briefly, the likely cost effectiveness of
the intervention. The additional number of prevent›
able deaths or events with full uptake is highly depend›
ent on the estimated current uptake rate. The few
studies that have examined these rates suggest that
uptake is low. Considerable improvements in health
outcomes would result if primary care groups with low
uptake of these interventions—apart from use of statins
for patients at low risk of coronary heart disease—
improved their uptake rates. For example, a locality
would prevent 24 deaths each year if all high risk
patients took aspirin rather than the 50% who
currently do so.
For these eight interventions that improve health
outcomes, table 5 lists the possible performance
indicators that could measure their use in primary care
groups. There are indicators of the proportion of the
population with diagnoses of hypertension, coronary
heart disease, atrial fibrillation, and heart failure. Com›
paring observed with expected proportions could
highlight inadequate detection of these diseases or
incomplete Read coding within primary care. Data
sources for all these indicators are available in practices
with well computerised records.
Methodological issues
Our sources of evidence were not comprehensive. We
selected the eight interventions because of the ease of
obtaining information, including the ability to translate
evidence on efficacy into improvement in health
outcomes at a population level. It would be possible to
use this method for other primary care interventions
and to overcome some of the difficulties listed in table
2. We used our sources of evidence in an illustrative
way to demonstrate the potential for developing
Table 3 Primary care interventions: relative risk reductions, eligible patients, numbers needed to treat, and total number of preventable deaths or events
Events measured
Relative risk reduction
(95% CI)*
No of eligible
patients in a
population of
100 000
No of patients
needed to treat to
prevent one event†
No of preventable
events if all eligible
patients receive
intervention Comments‡
Aspirin for patients at high risk of coronary or ischaemic cerebrovascular events
Total deaths over 1 year 17% (11% to 23%)21 3 00022 62 48 Trials reviewed varied in length of follow up.
Largest benefits were seen in first year of follow
up. Side effects can be a problem and include
intracerebral and gastrointestinal haemorrhage
Vascular deaths over 1 year 18% (12% to 24%)21 67 45 MI, stroke, or
vascular deaths
Non›fatal MI over 1 year 35% (27% to 43%)21 68 44
Non›fatal stroke over 1 year 31% (21% to 41%)21 111 27
Control of hypertension
Total mortality over 4 years 16% (4% to 27%)23 17 88824 63 286 There is inconsistency in what constitutes
controlled hypertension. Side effects can be a
problem
CHD deaths over 4 years 25% (13% to 36%)23 100 179
Cerebrovascular deaths over 4 years 43% (21% to 58%)23 116 154
Advice on stopping smoking or nicotine replacement therapy
Total deaths over 1 year§ 13% 30 00024 256 120 Relative risk reduction extrapolated from a UK
cohort and may be an overestimate because of
confounding
Angiotensin converting enzyme inhibitors for patients with heart failure
Total deaths over 90 days§ 23% (12% to 33%)25 1 50026 20 76 Patients in many of the trials were younger than
those in the general population
Statins for patients at high risk of coronary heart disease (secondary prevention)
Total deaths over 5 years 30% (15% to 42%)27 1 96828 29 69 Cholesterol lowering is only one of many
possibilities to reduce CHD risk. Stroke risk may
also be reduced. Essentially, all the deaths
prevented were coronary deaths
All coronary deaths over 5 years 42% (17% to 54%)27 28 70
Major coronary events over 5 years 34% (25% to 41%)27 13 154
Statins for patients at low risk of coronary heart disease (primary prevention)
Total deaths over 5 years 22% (0 to 40%)29 1 39428 111 14 CHD rates have been falling in UK for two
decades. This must be taken into account when
making projections of population benefits from
interventions such as lipid lowering drugs
CHD deaths over 5 years 28% (−10% to 52%)29 155 9
CHD events over 5 years 31% (17% to 43%)29 41 34
Warfarin for stroke prophylaxis in non›valvular atrial fibrillation
Deaths over 1 year 33% (9% to 51%)30 1 90031 56 33 Side effects can be a problem and include
intracerebral haemorrhage. Pooled data were
from hospital based trialsStroke events over 1 year 68% (50% to 79%) 33 58
Influenza vaccination for those aged >65
Deaths each year 68% (56% to 76%)32 15 70034 108 146 Effectiveness of vaccine depends on vaccine
strain being sufficiently similar to epidemic
strainInfluenza episodes each year 58% (26% to 77%)
33 57 273
MI=myocardial infarction; CHD=coronary heart disease.
*Reduced risk of death or events for those receiving the intervention compared with those not receiving it.
†Calculated from the attributable risk reduction presented in the appendices available on the BMJ website.
‡References for these statements appear in the appendices available on the BMJ website.
§We were unable to calculate other events from the studies that we used.
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performance indicators based on interventions of
proved efficacy.
We used end points from randomised controlled
trials based in primary care, which are usually mortality
and major non›fatal events. These end points for
events such as further strokes or myocardial infarction
are defined variously as, for example, “major coronary
events,” “vascular deaths,” and “coronary heart disease
events.” The terms presented in the tables are those
used in the relevant trials. These events are rare within
an individual general practice and underestimate the
burden of morbidity.
Our method at present takes no account of years of
life lost or the difference between prevalent and
incident cases. We used prevalent cases, and we recog›
nise that absolute gains would fall over time. The
effects of the interventions included are over different
time scales, and there are wide confidence intervals for
the size of these effects and estimates of prevalence.
The effect is also dependent on patient compliance;
patient preferences and contraindications would
further reduce the number eligible for these interven›
tions. We interpreted odds ratios reported in systematic
reviews as relative risks and may have therefore
overstated any effect size.35 Interventions interact in
complex ways, but our method presents them in isola›
tion. We only briefly mention potential side effects and
likely cost effectiveness of these interventions. Ideally,
we would want to compare the overall cost per life year
gained for each intervention.
Despite these methodological difficulties, we
believe that this approach is a useful complement to
that used by the NHS Executive and Department of
Health in developing performance indicators relevant
to primary care. Our method identifies those interven›
tions that are attributable to primary care and
estimates the relative importance of these in terms of
reduced mortality or non›fatal events. It helps to
emphasise the importance of examining healthcare
needs both at the individual and population levels by
taking into account the prevalence of conditions and
the current uptake of interventions. This method could
be used to develop performance indicators for areas
other than primary care.
Requirements for developing evidence
based indicators
Before using the indicators proposed in table 5 it is
essential to develop clear definitions of the numerators
and denominators for each indicator. Sufficient
numbers and standard definitions are required to
enable comparisons between practices in a primary
care group. Indicators require evaluation both before
and after their introduction into routine use to fulfil
practical and scientific criteria.36 We are currently
attempting to derive and evaluate the indicators in
table 5 for all patients aged 45›69 in 19 local practices
of a future primary care group. These indicators
require collection of extra data, and some might
argue that primary care teams cannot cope with yet
more tasks. However, in the United Kingdom well
over a million hours every month are already spent
collecting data in primary care,37 and yet there is
little consensus on which data should be collected.
Focusing data collection on meaningful indicators and
abandoning it in less relevant areas could result in an
overall reduction in workload. If the government is to
use performance indicators as a method of improving
health and health care it is important to encourage
health professionals to focus on data collection linked
to interventions over which they have substantial
control and which improve health outcomes.
Table 4 Primary care interventions: estimated current uptake, additional number of preventable deaths or events with full uptake in a
population of 100 000, and likely cost effectiveness
Intervention
Estimated current
uptake among eligible
patients (%)*
Additional No of preventable deaths or
events with full uptake Likely cost effectiveness†
Aspirin for patients at high risk of
coronary or ischaemic
cerebrovascular events
50 24 deaths over 1 year; 22 vascular deaths
over 1 year; 22 non›fatal MIs over 1 year;
59 non›fatal strokes over 1 year
Likely to be cost effective
Control of hypertension 40 171 deaths over 4 years; 107 CHD deaths
over 4 years; 92 cerebrovascular deaths
over 4 years
Very cost effective for first line drugs, but less so
for more expensive drugs and for older people
Advice on stopping smoking or
nicotine replacement therapy
34 79 deaths over 1 year Likely to be cost effective
Angiotensin converting enzyme
inhibitors for patients with heart
failure
20 60 deaths over 90 days Likely to be cost effective, especially if treatment
started in primary care. The SOVLD trial showed a
reduction in hospital admissions of 30% in those
receiving the drug
Statins for patients at high risk of
coronary heart disease (secondary
prevention)
25 52 deaths over 5 years; 53 coronary
deaths over 5 years; 116 major coronary
events over 5 years
Greatest in patients with highest risk for CHD.
Should be used in patients with additional risk
factors
Statins for patients at low risk of
coronary heart disease (primary
prevention)
25 11 deaths over 5 years; 7 CHD deaths
over 5 years; 25 CHD events over 5 years
Should be used in patients with additional risk
factors. Cost effectiveness low in patients with no
previous MI or angina
Warfarin for stroke prophylaxis in
non›valvular atrial fibrillation
30 23 deaths each year; 40 stroke events
each year
Cost effective, especially if at least one additional
risk factor for stroke
Influenza vaccination for those aged
>65
30 102 deaths each year; 191 influenza
episodes each year
Likely to be cost effective. UK government has
recently recommended that all those aged >75
should receive vaccine
MI=myocardial infarction; CHD=coronary heart disease.
*Details on how we calculated the estimated current uptake rates are in the appendices available on the BMJ website.
†References for these statements appear in the appendices available on the BMJ website.
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Comparison with the performance
indicators currently proposed
There are considerable differences between the
evidence based performance indicators that we gener›
ated (table 5) and those in the national framework for
assessing performance relevant to primary care (table
1). Some of the latter are important, relating to
efficiency and access, but many of the others could cre›
ate perverse incentives to change practice.38 39 For
example, the indicators relating to district nurses may
encourage district nurses to reduce the number of
appropriate visits to patients aged under 75 years.
Similarly, in order to seem to “perform” well, general
practitioners may reduce the number of appropriate
hospital admissions for anyone aged over 75 or those
with pyelonephritis, heart failure, or asthma. They may
even stop notifying pertussis or measles. Our evidence
based indicators may be less likely to encourage
perverse incentives as they are based on robust
evidence. However, health authorities and primary
care groups would have to use such indicators
appropriately and ensure that the risks and benefits of
interventions were considered, especially in elderly
patients.
Conclusions
Applying evidence from clinical trials and systematic
reviews to individual patients in primary care is
complex and challenging.40 Overcoming operational
issues and changing clinical behaviour require a multi›
faceted approach.41 42 The use of performance indica›
tors by themselves as a method to improve the
effectiveness of health care in primary care groups is
unlikely to succeed. However, the use of evidence based
Table 5 Primary care interventions that improve health outcomes and possible performance indicators that reflect their use
Intervention and possible indicators Evidence that improved indicator value reflects improved health outcomes
Aspirin for patients at high risk of coronary or ischaemic cerebrovascular events
% of population with diagnosis of IHD Yes, if appropriate treatment follows diagnosis. Need to compare observed and
expected prevalence to estimate undetected IHD
% of population with diagnosis of IHD who take aspirin* Yes, but need to ensure that observed prevalence of IHD is similar to expected.
Need to record advice to buy aspirin
% of population with a diagnosis of ischaemic stroke or TIAs† Yes, if appropriate treatment follows diagnosis. Need to compare observed and
expected prevalence to estimate undetected stroke or TIAs
% of population with diagnosis of ischaemic stroke or TIAs who take aspirin* Yes, but need to ensure that observed prevalence of stroke and TIAs is similar to
expected. Need to record advice to buy aspirin
Control of hypertension
% of population whose BP recorded in past 5 years*† Yes, if appropriate treatment follows diagnosis
% of population with diagnosis of hypertension Yes, if appropriate treatment follows diagnosis. Need to compare observed and
expected prevalence to estimate undetected hypertension
% of population identified as hypertensive whose most recent systolic BP
<160 mm Hg*
Yes, but need to ensure that observed prevalence of hypertension is similar to
expected
% of population identified as hypertensive whose most recent diastolic BP
<90 mm Hg
Yes, but need to ensure that observed prevalence of hypertension is similar to
expected
% of population identified as hypertensive whose BP recorded in past year† Yes, if appropriate treatment follows a set of abnormal readings
% of those with diagnosis of IHD whose BP recorded in past year† Yes, if appropriate treatment follows a set of abnormal readings
% of those with diagnosis of ischaemic stroke or TIA whose BP recorded in past
year
Yes, if appropriate treatment follows a set of abnormal readings
Advice on stopping smoking or nicotine replacement therapy
% of population whose smoking status recorded Yes, if appropriate treatment follows recording status as current smoker
% of population who are current smokers and have received advice on stopping
smoking or nicotine replacement therapy
Yes
% of those with diagnosis of IHD whose smoking status recorded Yes, if appropriate treatment follows recording status as current smoker
% of those with diagnosis of IHD who are current smokers who have received
advice on stopping smoking or nicotine replacement therapy
Yes
% of those with a diagnosis of ischaemic stroke or TIA who have their smoking
status recorded
Yes, if appropriate treatment follows recording status as current smoker
% of those with a diagnosis of ischaemic stroke or TIA who are current smokers
who have received smoking cessation advice or nicotine replacement therapy
Yes
Use of angiotensin converting enzyme inhibitors in those with heart failure
% of population with a diagnosis of heart failure Yes, if appropriate treatment follows diagnosis. Need to compare observed and
expected prevalence to estimate undetected heart failure
% of population with heart failure who have a prescription for ACE inhibitors Yes, if diagnosis is confirmed by echocardiography
Lipid lowering drugs for patients with established cardiovascular disease
% of those with a diagnosis of IHD who have had a cholesterol measurement Yes, if appropriate treatment follows diagnosis
% of those with a diagnosis of IHD with a raised cholesterol who are prescribed
lipid lowering drugs
Yes
Warfarin for stroke prophylaxis in NVAF
% of population with diagnosis of NVAF Yes, if appropriate treatment follows diagnosis. Need to compare observed and
expected prevalence to estimate undetected NVAF
% of general practice patients with diagnosis of NVAF who have a prescription
for anticoagulants
Yes, need to ensure that observed prevalence of NVAF is similar to expected
Influenza vaccination in those aged over 65 years
% of population aged >65 who receive annual influenza vaccination Yes
IHD=ischaemic heart disease; TIA=transient ischaemic attack; BP=blood pressure; ACE=angiotensin converting enzyme; NVAF=non›valvular atrial fibrillation
All these indicators are attributable to health care.
*Similar indicators may be suggested by Department of Health commissioned expert groups examining a wide range of indicators for both stroke and myocardial
infarction (M Goldacre, personal communication).
†Similar indicators presented in US National Library of Healthcare Indicators.11
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indicators linked to interventions that improve health
outcomes, such as those suggested in table 5, could be
an important adjunct if used in interactive practice or
primary care group educational meetings.43 Primary
care group indicators should be based on robust
evidence. If not, their use is unlikely to lead to
improved health outcomes. Our method may be a
complementary way of identifying areas for perform›
ance indicators to those proposed by the NHS Execu›
tive and Department of Health. Our suggested
indicators are more likely to help turn evidence into
everyday practice and to have an impact on the popu›
lation’s health.
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Endpiece
The philosopher and the chicken
A story is told about Sir Isaac Newton when he was
living in London toward the end of his life. His
intimate friend Dr. [William] Stukel[e]y, who had
been deputy to Dr. [Edmond] Halley as secretary to
the Royal Society, was one day shown into Sir
Isaac’s dining›room, where his dinner had been for
some time served up. Dr. Stukel[e]y waited for a
considerable time, and getting impatient, he
removed the cover from a chicken, which he ate,
replacing the bones under the cover. In a short
time Sir Isaac entered the room, and after the usual
compliments sat down to his dinner, but on taking
off the cover, and seeing nothing but bones, he
remarked, “How absent we philosophers are. I
really thought that I had not dined.”
Historical Embodiments of Natural Knowledge,
ed Christopher Lawrence, Steven Shapi (1998)
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